- Leidos (NYSE:LDOS) announces signing a Memorandum of Understanding with Biosortia Pharmaceuticals to focus on identifying and advancing immunotherapeutic opportunities including inmuno-oncology.
- The companies will combine existing and future assets enabling them to deliver de-risked assets to a pharmaceutical partner for development.
- Leidos has various immune checkpoint inhibitor peptides and data analytics technologies that combine with Biosortia’s microbiome harvesting and mining tech.
- Press release